Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroxine-binding globulin (TBG) is a glycoprotein primarily synthesized in the liver that serves as the main high-affinity transport protein for thyroid hormones (T4 and T3) in the blood. While TBG is not a direct therapeutic target, its serum concentration is crucial for interpreting thyroid function tests. Changes in TBG levels, influenced by factors such as pregnancy, certain medications, and genetic variations, alter total circulating thyroid hormone levels without necessarily affecting free hormone levels or clinical status. Inherited TBG deficiencies are usually benign but diagnostically important to avoid misinterpreting thyroid function tests.
TBG levels are affected by several drugs. Estrogens/oral contraceptives increase TBG production, and androgens/anabolic steroids/glucocorticoids decrease TBG production. This, in turn, affects the total T4/T3 levels but typically not the free T4/T3 levels.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thyroxine-binding globulin (TBG).